Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
Colorcon
Dow
AstraZeneca
Johnson and Johnson

Last Updated: October 6, 2022

Details for Patent: 8,367,701


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 8,367,701 protect, and when does it expire?

Patent 8,367,701 protects XIIDRA and is included in one NDA.

This patent has thirty-nine patent family members in eight countries.

Summary for Patent: 8,367,701
Title:Crystalline pharmaceutical and methods of preparation and use thereof
Abstract: Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention. ##STR00001##
Inventor(s): Burnier; John (Pacifica, CA), Gadek; Thomas (Oakland, CA), Naud; Frederic (Binningen, CH)
Assignee: SARcode Bioscience Inc. (Brisbane, CA)
Application Number:13/289,172
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,367,701
Patent Claim Types:
see list of patent claims
Composition; Compound; Use; Formulation; Delivery;

Drugs Protected by US Patent 8,367,701

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis XIIDRA lifitegrast SOLUTION/DROPS;OPHTHALMIC 208073-001 Jul 11, 2016 RX Yes Yes See Plans and Pricing See Plans and Pricing Y TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED) See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,367,701

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2008317473 See Plans and Pricing
Canada 2702984 See Plans and Pricing
Canada 2958665 See Plans and Pricing
Canada 3105972 See Plans and Pricing
China 101873797 See Plans and Pricing
China 102056485 See Plans and Pricing
China 102065694 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Express Scripts
Johnson and Johnson
Baxter
Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.